Linked Data API

Show Search Form

Search Results

418453
registered interest false more like this
date less than 2015-09-11more like thisremove minimum value filter
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Cancer Drugs Fund more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what assessment he has made of the effect on cancer clinical trials of NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement. more like this
tabling member constituency Scunthorpe more like this
tabling member printed
Nic Dakin more like this
uin 10093 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-09-16more like thismore than 2015-09-16
answer text <p>Neither the Department nor NHS England has made any such assessment.</p><p> </p><p> </p><p> </p><p>Advances in medical science means that new cancer medicines are emerging all the time and NHS England needs to regularly prioritise its national Cancer Drugs Fund (CDF) list so people can access these too. Decisions on which treatments are included on the list are made by the CDF expert clinical panel because it is right these decisions are clinically led.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2015-09-16T15:25:30.407Zmore like thismore than 2015-09-16T15:25:30.407Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4056
label Biography information for Nic Dakin more like this